aCL-IgG/IgM, anti-β2GPI, and LA in patients with thrombocytopenia (OR 2.93, 95% CI 1.31–6.56, p = 0.009) were associated with increased mortality rate compared with patients who had APS without thrombocytopenia [96]. This evidence concerns the gene CD40LG and Thrombocytopenia.